Combination therapies for treatment of cancer
Combination therapies for treatment of cancers associated with mutations in the KRAS gene are provided. Compositions comprising therapeutic agents for treatment of cancers associated with mutations in the KRAS gene are also provided.
1. A method for treating a KRAS G12C mutant cancer, the method comprising administering an effective amount of a KRAS G12C mutant modulating compound and an additional therapeutic agent to a subject in need thereof, wherein the KRAS G12C mutant modulating compound has the following structure (I′b):
or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein:
X and Y are each independently N or CR 6 ;
Z is N or CR 6a ;
L 1 is a bond;
L 2 is a bond or alkylene;
R′ is R 1 and R″ is R 2c ; or R′ is H and R″ is R 1 ;
R 1 is substituted or unsubstituted aryl or heteroaryl;
R 2a , R 1b and R 2C are each independently H, halo, hydroxyl, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 alkoxy, C 3 -C 8 cycloalkyl or aryl;
R 3a and R 3b are, at each occurrence, independently H, —OH, —NH 2 , —CO 2 H, halo, cyano, C 1 -C 6 alkyl, C 1 -C 6 alkynyl, hydroxylalkly, aminylalkyl, alkylaminylalkyl, cyanoalkyl, carboxyalkyl, aminocarbonylalkyl or aminocarbonyl;
R 4a and R 4b are, at each occurrence, independently H, —OH, —NH 2 , —CO 2 H, halo, cyano, C 1 -C 6 alkyl, C 1 -C 6 alkynyl, hydroxylalkly, aminylalkyl, alkylaminylalkyl, cyanoalkyl, carboxyalkyl, aminocarbonylalkyl or aminocarbonyl;
R 6 is, at each occurrence, independently H, cyano, cyanoalkyl, amino, aminylalkyl, aminylalkylaminyl, aminocarbonyl, alkylaminyl, haloalkylamino, hydroxylalkyamino, amindinylalkyl, amidinylalkoxy, amindinylalkylaminyl, guanidinylalkyl, guanidinylalkoxy, guanidinylalkylaminyl, C 1 -C 6 alkoxy, aminylalkoxy, alkylcarbonylaminylalkoxy, C 1 -C 6 alkyl, heterocyclyl, heterocyclyloxy, heterocyclylalkyloxy, heterocyclylamino, heterocyclylalkylamino, heteroaryl, heteroaryloxy, heteroarylalkyloxy, heteroarylamino, heteroarylalkylamino, aryl, aryloxy, arylamino, arylalkylamino or arylalkyloxy;
R 6a is H or C 1 -C 6 alkyl;
represents a double or triple bond;
Q is —C(═O)-, —C(═NR 8′ )—, —NR 8 C(═O)-, —S(═O) 2 - or —NR 8 S(═O) 2 -;
R 8 is H, C 1 -C 6 alkyl or hydroxylalkyl;
R 8′ is H, —OH, —CN or C 1 -C 6 alkyl; and
when is a double bond then R 9 and R 10 are each independently H, cyano, carboxyl, C 1 -C 6 alkyl, alkoxycarbonyl, aminylalkyl, alkylaminylalkyl, or hydroxylalkyl or R 9 and R 10 join to form a carbocyclic or heterocyclic ring,
provided at least one of X, Y and Z is N,
wherein the KRAS mutant cancer is a pancreatic cancer, a colorectal cancer or a lung cancer.
2. The method of claim 1 , wherein the additional therapeutic agent is a phosphatidylinositol-3 kinase (PI3K) inhibitor.
3. The method of claim 2 , wherein the phosphatidylinositol kinase (PI3K) inhibitor is GDC0941, MLN1117, BYL719 (Alpelisib) or BKM120 (Buparlisib).
4. The method of claim 1 , wherein the additional therapeutic agent is a protein kinase inhibitor.
5. The method of claim 4 , wherein the protein kinase inhibitor is Afatinib, Axitinib, Bevacizumab, Bostutinib, Cetuximab, Crizotinib, Dasatinib, Erlotinib, Fostamatinib, Gefitinib, Imatinib, Lapatinib, Lenvatinib, Ibrutinib, Nilotinib, Panitumumab, Pazopanib, Pegaptanib, Ranibizumab, Ruxolitinib, Sorafenib, Sunitinib, SU6656, Trastuzumab, Tofacitinib, Vandetanib or Vemurafenib.
6. A method for inducing apoptosis in a cell population comprising a KRAS G12C mutant protein, the method comprising administering an effective amount of a KRAS G12C mutant modulating compound and an additional therapeutic agent to the cell population, wherein the KRAS G12C mutant modulating compound has the following structure (I′b):
or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein:
X and Y are each independently N or CR 6 ;
Z is N or CR 6a ;
L 1 is a bond;
L 2 is a bond or alkylene;
R′ is R 1 and R″ is R 2c ; or R′ is H and R″ is R 1 ;
R 1 is substituted or unsubstituted aryl or heteroaryl;
R 2a , R 2b and R 2C are each independently H, halo, hydroxyl, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 alkoxy, C 3 -C 8 cycloalkyl or aryl;
R 3a and R 3b are, at each occurrence, independently H, —OH, —NH 2 , —CO 2 H, halo, cyano, C 1 -C 6 alkyl, C 1 -C 6 alkynyl, hydroxylalkly, aminylalkyl, alkylaminylalkyl, cyanoalkyl, carboxyalkyl, aminocarbonylalkyl or aminocarbonyl;
R 4a and R 4b are, at each occurrence, independently H, —OH, —NH 2 , —CO 2 H, halo, cyano, C 1 -C 6 alkyl, C 1 -C 6 alkynyl, hydroxylalkly, aminylalkyl, alkylaminylalkyl, cyanoalkyl, carboxyalkyl, aminocarbonylalkyl or aminocarbonyl;
R 6 is, at each occurrence, independently H, cyano, cyanoalkyl, amino, aminylalkyl, aminylalkylaminyl, aminocarbonyl, alkylaminyl, haloalkylamino, hydroxylalkyamino, amindinylalkyl, amidinylalkoxy, amindinylalkylaminyl, guanidinylalkyl, guanidinylalkoxy, guanidinylalkylaminyl, C 1 -C 6 alkoxy, aminylalkoxy, alkylcarbonylaminylalkoxy, C 1 -C 6 alkyl, heterocyclyl, heterocyclyloxy, heterocyclylalkyloxy, heterocyclylamino, heterocyclylalkylamino, heteroaryl, heteroaryloxy, heteroarylalkyloxy, heteroarylamino, heteroarylalkylamino, aryl, aryloxy, arylamino, arylalkylamino or arylalkyloxy;
R 6a is H or C 1 -C 6 alkyl;
represents a double or triple bond;
Q is —C(═O)—, —C(═NR 8′ )-, —NR 8 C(═O)-, —S(═O) 2 - or —NR 8 S(═O) 2 -;
R 8 is H, C 1 -C 6 alkyl or hydroxylalkyl;
R 8′ is H, —OH, —CN or C 1 -C 6 alkyl; and
when is a double bond then R 9 and R 10 are each independently H, cyano, carboxyl, C 1 -C 6 alkyl, alkoxycarbonyl, aminylalkyl, alkylaminylalkyl, or hydroxylalkyl or R 9 and R 10 join to form a carbocyclic or heterocyclic ring,
provided at least one of X, Y and Z is N.
7. A method for inhibiting G12C mutant protein in a subject, the method comprising administering an effective amount of a KRAS G12C mutant modulating compound and an additional therapeutic agent to the subject, wherein the KRAS G12C mutant modulating compound has the following structure (I′b):
or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein:
X and Y are each independently N or CR 6 ;
Z is N or CR 6a ;
L 1 is a bond;
L 2 is a bond or alkylene;
R′ is R 1 and R″ is R 2c ; or R′ is H and R″ is R 1 ;
R 1 is substituted or unsubstituted aryl or heteroaryl;
R 2a , R 2b and R 2C are each independently H, halo, hydroxyl, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 alkoxy, C 3 -C 8 cycloalkyl or aryl;
R 3a and R 3b are, at each occurrence, independently H, —OH, —NH 2 , —CO 2 H, halo, cyano, C 1 -C 6 alkyl, C 1 -C 6 alkynyl, hydroxylalkly, aminylalkyl, alkylaminylalkyl, cyanoalkyl, carboxyalkyl, aminocarbonylalkyl or aminocarbonyl;
R 4a and R 4b are, at each occurrence, independently H, —OH, —NH 2 , —CO 2 H, halo, cyano, C 1 -C 6 alkyl, C 1 -C 6 alkynyl, hydroxylalkly, aminylalkyl, alkylaminylalkyl, cyanoalkyl, carboxyalkyl, aminocarbonylalkyl or aminocarbonyl;
R 6 is, at each occurrence, independently H, cyano, cyanoalkyl, amino, aminylalkyl, aminylalkylaminyl, aminocarbonyl, alkylaminyl, haloalkylamino, hydroxylalkyamino, amindinylalkyl, amidinylalkoxy, amindinylalkylaminyl, guanidinylalkyl, guanidinylalkoxy, guanidinylalkylaminyl, C 1 -C 6 alkoxy, aminylalkoxy, alkylcarbonylaminylalkoxy, C 1 -C 6 alkyl, heterocyclyl, heterocyclyloxy, heterocyclylalkyloxy, heterocyclylamino, heterocyclylalkylamino, heteroaryl, heteroaryloxy, heteroarylalkyloxy, heteroarylamino, heteroarylalkylamino, aryl, aryloxy, arylamino, arylalkylamino or arylalkyloxy;
R 6a is H or C 1 -C 6 alkyl;
represents a double or triple bond;
Q is —C(═O)—, —C(═NR 8′ )-, —NR 8 C(═O)-, —S(═O) 2 - or —NR 8 S(═O) 2 -;
R 8 is H, C 1 -C 6 alkyl or hydroxylalkyl;
R 8 is H, —OH, —CN or C 1 -C 6 alkyl; and
when is a double bond then R 9 and R 10 are each independently H, cyano, carboxyl, C 1 -C 6 alkyl, alkoxycarbonyl, aminylalkyl, alkylaminylalkyl, or hydroxylalkyl or R 9 and R 10 join to form a carbocyclic or heterocyclic ring,
provided at least one of X, Y and Z is N.
8. The method of claim 1 , 6 or 7 , wherein:
represents a double bond;
Q is —C(═O)—, —C(═NR 8′ )-, —NR 8 C(═O)-, —S(═O) 2 - or —NR 8 S(═O) 2 -;
R 8 is H, C 1 -C 6 alkyl or hydroxylalkyl;
R 8′ is H, —OH, —CN or C 1 -C 6 alkyl; and
R 9 and R 10 are each independently H, cyano, C 1 -C 6 alkyl, aminylalkyl, alkylaminylalkyl, or hydroxylalkyl or R 9 and R 10 join to form a carbocyclic or heterocyclic ring.
9. The method of claim 8 , wherein Q is —C(═O)—, and R 9 and R 10 are each H.
10. The method of claim 1 , 6 or 7 , wherein the G12C mutant modulating compound has the following structure:
11. The method of claim 1 , 6 or 7 , wherein X and Z are N, and Y is CR 6 .
12. The method of claim 1 , 6 or 7 , wherein R 1 is substituted or unsubstituted phenyl or substituted or unsubstituted naphthyl.
13. The method of claim 1 , 6 or 7 , wherein R 1 has one of the following structures:
14. The method of claim 1 , 6 or 7 , wherein R 2a and R 2b are each independently H or halo.
15. The method of claim 1 , 6 or 7 , wherein the KRAS G12C mutant modulating compound has one of the following structures:
16. The method of claim 1 , 6 or 7 , wherein the additional therapeutic agent is an epidermal growth factor receptor (EGFR) inhibitor, phosphatidylinositol kinase (PI3K) inhibitor, insulin-like growth factor receptor (IGF1R) inhibitor, Janus kinase (JAK) inhibitor, a Met kinase (MET) inhibitor, a SRC family kinase (SFK) inhibitor, a mitogen-activated protein kinase (MEK) inhibitor, an extracellular-signal-regulated kinase (ERK) inhibitor, mechanistic target of rapamycin (mTOR) inhibitor, a topoisomerase inhibitor, a taxane, an anti-metabolite agent, an alkylating agent or a taxane.
17. The method of claim 16 , wherein the additional therapeutic agent is an epidermal growth factor receptor (EGFR) inhibitor.
18. The method of claim 17 , wherein the epidermal growth factor receptor (EGFR) inhibitor is Erlotinib, Afatinib or Iressa.
19. The method of claim 1 , 6 or 7 wherein the compound and the additional therapeutic agent are co-administered.
20. The method of claim 1 , 6 or 7 wherein the compound and the additional therapeutic agent are separately administered.